Biotech: Page 25
-
Brian Tucker/BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 22, 2024 -
Permission granted by InterVenn Biosciences
Sponsored by InterVenn BiosciencesBreakthroughs in immunotherapy: glycoproteins as predictive biomarkers for therapeutic response
Serum-based glycoproteins demonstrate success in predicting immune checkpoint inhibitor therapy outcomes.
July 22, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
By BioPharma Dive staff • July 19, 2024 -
Getty Images
Immune resetArtiva prices $167M IPO, riding optimism for autoimmune cell therapy
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
By Ben Fidler • July 18, 2024 -
Getty Images
Caribou lays off staff; Roche walks away from Relay
Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.
By BioPharma Dive staff • July 17, 2024 -
Getty Images
NGM, now private, raises $122M for redrawn research plans
The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.
By Delilah Alvarado • July 17, 2024 -
Getty Images
Cardurion raises another $260M to fuel heart drug pipeline
The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines.
By Jonathan Gardner • July 16, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex taps Orum to hunt for better ‘preconditioning’ drugs
The deal gives Vertex rights to use Orum’s ADC-like technology to discover gentler preparatory regimens for patients receiving intensive treatments like Casgevy.
By Gwendolyn Wu • July 16, 2024 -
Permission granted by Sionna Therapeutics
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
The startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.
By Ben Fidler • July 16, 2024 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Asceneuron raises another $100M for Alzheimer’s drug development
The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.
By Jacob Bell • July 16, 2024 -
Getty Images
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.
By Ned Pagliarulo • July 15, 2024 -
Getty Images
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.
By BioPharma Dive staff • July 12, 2024 -
Getty Images
AbbVie names new R&D head; Arcutis eczema cream approved
Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.
By BioPharma Dive staff • July 10, 2024 -
Jerod Harris via Getty Images
Flagship raises $3.6B for biotech investing
The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.
By Kristin Jensen • July 10, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx, with GLP-1 buy, doubles down on blood sugar drugs
Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.
By Jacob Bell • July 10, 2024 -
Getty Images
SciRhom pulls in $70M for a new type of immune disease drug
The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.
By Gwendolyn Wu • July 9, 2024 -
Joe Raedle via Getty Images
HilleVax’s norovirus vaccine ineffective in large trial of infants
Shares in HilleVax plummeted after the company reported its experimental shot failed to meet the primary and secondary goals of the Phase 2b study.
By Delilah Alvarado • July 8, 2024 -
Getty Images
Ligand to buy Apeiron; Roche reports another TIGIT setback
Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.
By BioPharma Dive staff • July 8, 2024 -
Permission granted by Myricx Bio
A London biotech raises $114M to hone a new ADC payload
Myricx Bio is developing a type of payload that it thinks could work in tumors resistant to the toxins contained in ADCs like Enhertu and Trodelvy.
By Gwendolyn Wu • July 8, 2024 -
Courtesy of CureVac
CureVac cuts jobs, licenses out vaccines to GSK
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
By Jacob Bell • July 3, 2024 -
Getty Images
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
Forbion led the startup’s Series B round. Elsewhere, Vertex got an FDA decision date for its “vanza triple” and Dupixent won a marketing green light in Europe for COPD.
By BioPharma Dive staff • July 3, 2024 -
Maddie Meyer via Getty Images
Moderna gets US funding for bird flu vaccine development
BARDA will provide Moderna with $176 million to advance late-stage testing of an H5 influenza shot, as health officials monitor animal outbreaks.
By Delilah Alvarado • July 2, 2024 -
Scott Olson via Getty Images
Eli Lilly inks another radiopharma deal, gaining option to buy startup
Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.
By Delilah Alvarado • July 1, 2024 -
Courtesy of UniQure
UniQure, with sale of plant, outsources Hemgenix manufacturing
The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.
By Ned Pagliarulo • July 1, 2024 -
Getty Images
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease
Like many of its cell therapy peers, Artiva, which originally sought an IPO in 2021, has shifted its strategy to ride a wave of investor interest in autoimmune disease research.
By Ben Fidler • July 1, 2024
Previous
